RECURSION PHARMACEUTICALS, INC. (RXRX) Total liabilities 2020–2025
RECURSION PHARMACEUTICALS, INC. (RXRX) total liabilities at each fiscal year-end, per SEC filings.
$343.3MFY2025 · since FY2020: $56.6M → $343.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $343.3M | -17.0% |
| FY2024 | $413.8M | +117.5% |
| FY2023 | $190.3M | -11.7% |
| FY2022 | $215.5M | +219.7% |
| FY2021 | $67.4M | +19.2% |
| FY2020 | $56.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice